What is the latest ARTEMISMED stock price?
The latest stored price for ARTEMISMED is Rs 338.50 as of 2026-09-18.
gimli
ARTEMISMED stock AI analysis
ARTEMISMED Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
ARTEMIS MED SERVICE LTD is a small-cap stock in Healthcare. This Gimli page shows the latest available ARTEMISMED price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹338.50
1W return
-2.88%
1M return
+8.44%
3M return
+31.13%
6M return
+46.89%
1Y return
+39.92%
Market cap
₹n/a
PE
n/a
PB
n/a
ROE
n/a
ROCE
n/a
RSI
57.95
Turnover
₹11.36 cr
Why it can matter in screens
- Momentum: ARTEMISMED is above 50DMA, above 200DMA; RSI is 57.95.
- Returns: 1D +2.31%, 1W -2.88%, 1M +8.44%, 3M +31.13%, 1Y +39.92%.
- Trend levels: 52W high ₹362.00, 52W low ₹253.20, off high -6.49%.
- Liquidity: latest turnover is ₹11.36 cr; volume vs 20D is +0.77%.
- Valuation/profitability: PE n/a, PB n/a, ROE n/a, ROCE n/a.
- Growth: 3Y sales CAGR +14.76%, 3Y profit CAGR +37.61%.
Quick Answers
Is ARTEMISMED above its 50DMA and 200DMA?
ARTEMISMED is above 50DMA, above 200DMA. The latest 50DMA is 309.60 and the latest 200DMA is 266.58.
What are ARTEMISMED PE, ROE and ROCE?
ARTEMISMED has PE n/a, ROE n/a, and ROCE n/a in Gimli's latest available snapshot.
How has ARTEMISMED performed recently?
ARTEMISMED has returned +8.44% over 1 month, +31.13% over 3 months, and +39.92% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 287.41 cr | 60.88 cr | 31.05 cr | 1.96 |
| 2026-03-31 | 287.02 cr | 59.39 cr | 30.28 cr | 1.90 |
| 2025-12-31 | 279.81 cr | 52.03 cr | 22.23 cr | 1.41 |
| 2025-09-30 | 282.35 cr | 58.27 cr | 30.00 cr | 1.90 |
| 2025-06-30 | 261.89 cr | 48.33 cr | 21.20 cr | 1.35 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 1,090.40 cr | 211.96 cr | 103.44 cr | 6.55 |
| 2025-03-31 | 946.18 cr | 182.76 cr | 83.46 cr | 5.36 |
| 2024-03-31 | 852.51 cr | 135.66 cr | 49.15 cr | 3.53 |
| 2023-03-31 | 721.46 cr | 100.92 cr | 39.69 cr | 2.86 |
| 2022-03-31 | 548.67 cr | 71.06 cr | 32.58 cr | 2.34 |
Balance sheet
No recent data available.
Cash flow
No recent data available.
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +58.39% | +12.29% | +2.40% | +1.30% | +20.76% | +0.00% |
| 2026-03-31 | +58.39% | +12.19% | +2.89% | +1.69% | +20.37% | +0.00% |
| 2025-12-31 | +58.39% | +12.47% | +2.91% | +1.69% | +20.08% | +0.00% |
| 2025-11-15 | +58.43% | +12.48% | +3.35% | +1.79% | +19.58% | +0.00% |
| 2025-09-30 | +66.53% | +0.37% | +4.27% | +2.01% | +21.81% | +0.00% |
| 2025-06-30 | +66.53% | +0.24% | +4.76% | +1.96% | +21.46% | +0.00% |
| 2025-03-31 | +67.17% | +0.31% | +5.04% | +1.96% | +20.39% | +44.53% |
| 2024-12-31 | +67.17% | +0.64% | +4.50% | +1.74% | +20.60% | +44.53% |
| 2024-09-30 | +67.17% | +0.22% | +3.60% | +1.22% | +21.92% | +44.53% |
| 2024-06-30 | +67.51% | +0.16% | +3.45% | +1.23% | +21.76% | +44.53% |
| 2024-03-31 | +68.03% | +0.10% | +2.61% | +0.79% | +22.08% | +0.00% |
| 2023-12-31 | +68.03% | +0.11% | +1.96% | +0.32% | +22.72% | +0.00% |
| 2023-09-30 | +68.03% | +0.09% | +1.52% | +0.07% | +23.18% | +0.00% |
| 2023-06-30 | +68.03% | +0.07% | +1.41% | +0.00% | +23.31% | +0.00% |
| 2023-03-31 | +68.92% | +0.00% | +1.38% | +0.00% | +22.44% | +0.00% |
| 2022-12-31 | +68.92% | +0.00% | +1.15% | +0.00% | +22.66% | +0.00% |
| 2022-09-30 | +69.27% | +0.00% | +0.90% | +0.00% | +22.52% | +0.00% |
| 2022-06-30 | +69.59% | +7.34% | +0.91% | n/a | n/a | +0.00% |
| 2022-03-31 | +69.82% | +7.37% | +1.10% | n/a | n/a | +0.00% |
| 2021-12-31 | +69.82% | +7.37% | +1.22% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 440,829.82 cr | 36.388220 | +15.50% | +11.45% |
| DIVISLAB | DIVI S LABORATORIES LTD | 248,876.81 cr | 85.407280 | +18.37% | +53.39% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 163,807.57 cr | 75.106636 | +17.33% | +35.67% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,608.22 cr | 65.670049 | +21.03% | +13.94% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 116,723.14 cr | 26.011308 | +16.04% | +10.70% |
| CIPLA | CIPLA LTD | 112,647.78 cr | 33.401961 | +10.25% | -11.64% |
| LAURUSLABS | LAURUS LABS LIMITED | 105,487.98 cr | 96.587446 | +21.77% | +111.64% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 102,122.47 cr | 70.799892 | +14.33% | -10.58% |
Try these prompts
- Analyze ARTEMIS MED SERVICE with valuation, momentum and industry peers
- Compare ARTEMISMED with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare ARTEMISMED with other Healthcare stocks
Data snapshot: 2026-09-18. Not investment advice.